jeudi 16 mars 2017

Onco Actu du 16 mars 2017


1.1 Biologie - Gènes

New breast cancer drugs could help more than previously thought [NHS Choices]

2.6 Etiologie - Environnement

European Chemicals Agency doesn’t classify glyphosate as a carcinogen – Expert Reaction [Science Media Centre]

No cancer risk to using glyphosate weedkiller, says EU watchdog [The Guardian]

EU chemical agency says weed killer glyphosate not carcinogenic [Reuters]

3.1 Tabac

Indonesia tobacco bill would fire up output despite health fears [Reuters]

4.12 Biopsies liquides

Biocartis and Merck partnership launch second liquid biopsy assay [European Pharmaceutical Review]

4.9 Dép., diag. & prono. - Sein

Breast cancer and the ballot box: political messages about screening prioritize votes over informed decisions [HealthNewsReview]

5. Traitements

Drug combination delivered by nanoparticles may help in melanoma treatment [Penn State Health]

Finding positive in the negative [Mass. General Hospital]

5.10 Traitements - Essais

Lynparza Phase III SOLO-2 data demonstrate progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy [AstraZeneca]

PARP Inhibitors Do It Again [In the Pipeline]

5.12 Immunothérapies

Immunotherapy may help treat kids’ brain tumors, preliminary Stanford study shows [Stanford Medicine]

Keytruda's head-to-head against Opdivo rockets meds to Nos. 2 and 3 in ad spending [FiercePharma]

5.2 Pharma

Biotech's PARP Wars Cool Down [Bloomberg]

Immunomedics lays out its case for an accelerated OK of IMMU-132 in triple-negative breast cancer [EndPoints]

5.2.3 Pharma - économie

Cell Medica raises £60M to push cancer therapies into clinic [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

Scott Gottlieb’s fervor for deregulation could harm patients [STAT]

Faster access to new drugs doesn’t always mean better treatment [The Conversation]

5.3.4 Traitements - AMM (FDA, EMA)

Merck's Keytruda nabs first blood-cancer nod, but rare cancer decision has to wait [FiercePharma]

FDA Grants Accelerated Approval to Pembrolizumab for the Treatment of Classical Hodgkin Lymphoma [ESMO]

FDA Approves Ribociclib as Initial Treatment for Postmenopausal Women with HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer [ESMO]

5.4 Traitements - Economie

Sticker Shock Forces Thousands Of Cancer Patients To Skip Drugs, Skimp On Treatment [KHN]

NICE drug expense limit of £20 million could cause treatment delays [Pharmafile]

Cancer patients skipping medicines or delaying treatment due to high drug prices [STAT]

NICE gets go-ahead to fast-track more drug approvals [NICE]

New UK drug cost rules leave companies fuming [Reuters]

Drugs costing 8p a day could be hit by 'devastating' NHS rationing plan [The Telegraph]

NHS patients could face wait to access life-saving drugs [The Guardian]

6. Lutte contre les cancers

What Young People Need to Know About Colon Cancer [NY Times]

6.10.1 Politiques (USA)

Trump budget calls for slashing biomedical and science research funding [STAT]

NIH would see huge budget cut under president’s proposal [Washington Post]

NIH, DOE Office of Science face deep cuts in Trump's first budget [Science]

FDA fees for product review would more than double under Trump budget [Reuters]

6.6 Publications

New Feature Alert! [ORCID]

Another correction for prominent cancer researcher who’s dodged accusations for decades [Retraction Watch]